HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
M 16209
structure given in first source
Also Known As:
1-(3-bromobenzo(b)furan-2-ylsulfonyl)hydantoin; M-16209; M16209; 2,4-Imidazolidinedione, 1-((3-bromo-2-benzofuranyl)sulfonyl)-
Networked:
7
relevant articles (
5
outcomes,
2
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Azoles: 2138
Imidazoles: 150
Imidazolidines: 39
Hydantoins: 306
M 16209: 7
Fused-Ring Heterocyclic Compounds
2-Ring Heterocyclic Compounds
Benzofurans: 26
M 16209: 7
Related Diseases
1.
Diabetes Complications
02/07/1991 - "
The present study indicates that M16209 and M16287 are potent aldose reductase inhibitors expected to be useful for the treatment of diabetic complications.
"
03/24/1995 - "
The antihyperglycemic activity of M16209, combined with its potent aldose reductase inhibiting activity, is expected to be beneficial in the treatment of diabetic complications.
"
06/01/1991 - "
These results indicate that M16209 and M16287 are potent aldose reductase inhibitors, which could be applicable to treatment for diabetic complications.
"
12/01/1990 - "
These results indicate that M16209 and M16287 can prevent galactose-induced cataract formation through amelioration of metabolic disorders and thus have high potential for clinical use in the treatment of some diabetic complications.
"
2.
Hyperglycemia
05/23/1996 - "
In C57BL/6J ob/ob mice, M16209 given for 28 days at doses of 30 and 100 mg/kg/day improved hyperinsulinemia, hyperglycemia and hypercholesterolemia without affecting body weight.
"
03/24/1995 - "
In diabetic rats, M16209 (100 mg/kg) significantly suppressed the hyperglycemia of streptozotocin-induced, mildly diabetic rats and stimulated serum glucose disappearance in neonatally streptozotocin-induced, non-insulin-dependent diabetes mellitus (NIDDM) rats in glucose tolerance tests.
"
3.
Diabetic Neuropathies (Diabetic Neuropathy)
02/07/1991 - "
Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats.
"
06/01/1991 - "
M16209 and M16287 were effective in the prevention of galactosemic cataracts and amelioration of diabetic neuropathy with almost the same potency, while ONO-2235 was effective only in neuropathy, and sorbinil was effective in galactosemic cataracts and diabetic neuropathy with a different potency.
"
4.
Type 2 Diabetes Mellitus (MODY)
03/24/1995 - "
These results suggest that M16209, unlike sulfonylureas, selectively enhances glucose-stimulated insulin secretion in both normal and NIDDM rats through a direct action on the pancreas.
"
03/24/1995 - "
In diabetic rats, M16209 (100 mg/kg) significantly suppressed the hyperglycemia of streptozotocin-induced, mildly diabetic rats and stimulated serum glucose disappearance in neonatally streptozotocin-induced, non-insulin-dependent diabetes mellitus (NIDDM) rats in glucose tolerance tests.
"
03/24/1995 - "
M16209 (100 microM) improved appreciably the decreased insulin response to 22.2 mM glucose and enhanced slightly unstimulated insulin secretion in the pancreases of rats with neonatally streptozotocin-induced, non-insulin-dependent diabetes mellitus (NIDDM).
"
03/24/1995 - "
Additionally, M16209 augmented insulin secretion in glucose-loaded, normal and NIDDM rats and restored the reduced serum insulin in streptozotocin-induced, mildly diabetic rats.
"
5.
Cataract (Cataracts)
12/01/1990 - "
These results indicate that M16209 and M16287 can prevent galactose-induced cataract formation through amelioration of metabolic disorders and thus have high potential for clinical use in the treatment of some diabetic complications.
"
06/01/1991 - "
M16209 and M16287 were effective in the prevention of galactosemic cataracts and amelioration of diabetic neuropathy with almost the same potency, while ONO-2235 was effective only in neuropathy, and sorbinil was effective in galactosemic cataracts and diabetic neuropathy with a different potency.
"
12/01/1990 - "
Effects of novel aldose reductase inhibitors, M16209 (1-(3-bromobenzo[b]furan-2-ylsulfonyl)hydantoin) and M16287 (1-(3-chlorobenzo[b]furan-2-ylsulfonyl)hydantoin), on galactose-induced cataract formation in rats were investigated.
"
Related Drugs and Biologics
1.
Aldehyde Reductase (Aldose Reductase)
2.
M 16287
3.
Glucose (Dextrose)
4.
Hypoglycemic Agents (Hypoglycemics)
5.
Streptozocin (Streptozotocin)
6.
Insulin (Novolin)
7.
epalrestat
8.
sorbinil
9.
Hydantoins
10.
furan
Related Therapies and Procedures
1.
Oral Administration